Clinical Trial

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2020 (before its estimated August 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC。
Trial Details
NCT Number NCT04481763
Lead Sponsor Jiangxi Provincial Cancer Hospital
Conditions Triple-Negative Breast Cancer
Enrollment 20 participants
Start Date 2020-07-14
Primary Completion 2024-08-30 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2020-07-22